教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Changes in brain natriuretic peptide in chronic heart failure patients treated with long-acting versus short-acting loop diuretics: J-MELODIC subanalysis. |
掲載誌名 | 正式名:Heart and vessels 略 称:Heart Vessels ISSNコード:1615-2573(Electronic)0910-8327(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 32(7),pp.865-71 |
著者・共著者 | Fukui Miho, Tsujino Takeshi, Hirotani Shinichi, Ito Hiroshi, Yamamoto Kazuhiro, Akasaka Takashi, Hirano Yutaka, Ohte Nobuyuki, Daimon Takashi, Nakatani Satoshi, Kawabata Masaaki, Masuyama Tohru |
発行年月 | 2017/07 |
概要 | We have previously reported that a long-acting loop diuretic, azosemide, reduces cardiovascular risks in patients with chronic heart failure (CHF) as compared with a short-acting one, furosemide, in Japanese Multicenter Evaluation of LOng- versus short-acting Diuretics In Congestive heart failure (J-MELODIC). However, the mechanisms of the difference have not been elucidated. This study aimed to examine whether there is a difference in the reduction in plasma brain natriuretic peptide (BNP) level and in left ventricular (LV) functional recovery between the CHF patients treated with the long-acting diuretic (the azosemide group) and the short-acting diuretic (the furosemide group). We reviewed changes in plasma BNP level and echo-assessed LV functional parameters from baseline to a year after the entry in 288 CHF patients with New York Heart Association class II or III symptoms that joined J-MELODIC. The decrease in plasma BNP levels was larger in the azosemide group than in the furosemide group (p < 0.01). The changes in echocardiographic parameters were not more favorable in the azosemide group than in the furosemide group. In conclusion, the decrease in plasma BNP levels was larger in the azosemide group than in the furosemide group. These findings may account for the better prognosis in CHF patients treated with azosemide than those with furosemide in J-MELODIC. |
DOI | 10.1007/s00380-017-0945-z |
PMID | 28105515 |